Obviously, new management really has things going in the right direction. Hopefully, the final approval for the new indication for oral hectoral capsules will come soon-this would have the potential to be indicated for several hundred thousand chronic kidney patients. One big concern was the impact from the new Amgen drug parathyroid hormone blocker due to be released soon. However, it appears that this will be used with Vit.D, not instead of it.
Yep, I agree, he has so much stock that he probably starts to dump it as the stock rises and then of course the stock falls! As I said in a previous posting, vicious circle! It should be a good buy however at this level.